Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.
Ropivacaine is indicated in adult patients for the induction of regional or local anesthesia for surgery or acute pain management.
Peking University People's Hospital, Beijing, Beijing, China
UF Health of University of Florida, Gainesville, Florida, United States
University of Kentucky Medical Center, Lexington, Kentucky, United States
The University of Michigan, Ann Arbor, Michigan, United States
Mayo Clinic in Florida, Jacksonville, Florida, United States
Mona Mohamed Mogahed, Tanta, Elgharbia, Egypt
Centre Hospitalier Universitaire de Nantes, Nantes, France
Centre Hospitalier Départemental Vendée, La Roche sur Yon, France
Clinique Mutualiste de l'Estuaire, Saint-Nazaire, France
Serviço de Otorrinolaringologia, Hospital de Braga, Braga, Portugal
UPMC Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.